Cargando…

Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence

In patients undergoing percutaneous coronary intervention (PCI), the standard of care is dual antiplatelet therapy with a P2Y(12) inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin. Current clinical practice guidelines now recommend more potent P2Y(12) inhibitors (prasugrel or ticagrelor)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gower, Megan N, Ratner, Lindsay R, Williams, Alexis K, Rossi, Joseph S, Stouffer, George A, Lee, Craig R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419635/ https://www.ncbi.nlm.nih.gov/pubmed/32821149 http://dx.doi.org/10.2147/PGPM.S231475

Ejemplares similares

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy
por: Nguyen, Anh B., et al.
Publicado: (2022)

Frequency and Clinical Outcomes of CYP2C19 Genotype-Guided Escalation and De-escalation of Antiplatelet Therapy in a Real-World Clinical Setting
por: Martin, Jesse, et al.
Publicado: (2019)

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
por: Beitelshees, Amber L., et al.
Publicado: (2022)

The use of dual antiplatelet therapy for ischemic cerebrovascular events
por: Mele, Francesco, et al.
Publicado: (2022)

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls
por: Ellithi, Moataz, et al.
Publicado: (2020)

Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention
por: Ramesh, S., et al.
Publicado: (2020)

CYP2C19 genotype-directed P(2)Y(12) inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention
por: Stys, Tomasz P., et al.
Publicado: (2021)

The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack
por: McDermott, John H, et al.
Publicado: (2022)

Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events
por: De Luca, Leonardo, et al.
Publicado: (2021)

CYP2D6 genotype and adverse events to risperidone in children and adolescents
por: Oshikoya, Kazeem A., et al.
Publicado: (2019)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
por: Cavallari, Larisa H., et al.
Publicado: (2018)

Evaluating the Extent of Reusability of CYP2C19 Genotype Data among Patients Genotyped for Antiplatelet Therapy Selection
por: Beitelshees, Amber L., et al.
Publicado: (2020)

Impact of the CYP2D6 Genotype on Metoprolol Tolerance and Adverse Events in Elderly Chinese Patients With Cardiovascular Diseases
por: Chen, Jianqiao, et al.
Publicado: (2022)

Prevalence and trends of perioperative major adverse cardiovascular and cerebrovascular events during cancer surgeries
por: Ramamoorthy, Venkataraghavan, et al.
Publicado: (2023)

Infarction Patterns and Recurrent Adverse Cerebrovascular Events in Moyamoya Disease
por: Yu, Shao-Chen, et al.
Publicado: (2022)

Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands
por: Deiman, B. A. L. M., et al.
Publicado: (2016)

Long‐Term Blood Pressure Variability and Major Adverse Cardiovascular and Cerebrovascular Events After Intracerebral Hemorrhage
por: Castello, Juan Pablo, et al.
Publicado: (2022)

Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack
por: Cai, Zeling, et al.
Publicado: (2021)

Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke
por: Tu, Wen-Jun, et al.
Publicado: (2020)

Influence of the Triglyceride-Glucose Index on Adverse Cardiovascular and Cerebrovascular Events in Prediabetic Patients With Acute Coronary Syndrome
por: Guo, Qianyun, et al.
Publicado: (2022)

Leukocyte subtypes and adverse clinical outcomes in patients with acute ischemic cerebrovascular events
por: Wang, Anxin, et al.
Publicado: (2021)

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
por: Bauer, Tim, et al.
Publicado: (2011)

Development and Validation of a Nomogram of In-hospital Major Adverse Cardiovascular and Cerebrovascular Events in Patients With Acute Coronary Syndrome
por: Bo, Xiangwei, et al.
Publicado: (2021)

Sex differences in major adverse cardiovascular and cerebrovascular event risk among central retinal artery occlusion patients
por: Chen, Ting, et al.
Publicado: (2023)

Prediction of major adverse cardiac, cerebrovascular events in patients with diabetes after acute coronary syndrome
por: Baluja, Aurora, et al.
Publicado: (2019)

Left atrial volume predicts adverse cardiac and cerebrovascular events in patients with hypertrophic cardiomyopathy
por: Tani, Tomoko, et al.
Publicado: (2011)

Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention
por: Patel, Vardhaman, et al.
Publicado: (2014)

Assessing risk factors for major adverse cardiovascular and cerebrovascular events during the perioperative period of carotid angioplasty with stenting patients
por: Liu, Juan, et al.
Publicado: (2016)

Novel Insight Into Long-Term Risk of Major Adverse Cardiovascular and Cerebrovascular Events Following Lower Extremity Arteriosclerosis Obliterans
por: Sun, Ji, et al.
Publicado: (2022)

A Preliminary Study on the Value of Intestinal Flora in Predicting Major Adverse Cardiovascular and Cerebrovascular Events in Patients with Refractory Hypertension
por: Jiao, Jie, et al.
Publicado: (2022)

Antiplatelet combinations for prevention of atherothrombotic events
por: Bollati, Mario, et al.
Publicado: (2011)

Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial
por: Shi, Xiujin, et al.
Publicado: (2021)

Impact of statin intensity on adverse cardiac and cerebrovascular events in older adult patients with myocardial infarction
por: Moon, In Tae, et al.
Publicado: (2021)

Major Adverse Cardiac and Cerebrovascular Events in Patients Undergoing Simultaneous Heart Surgery and Carotid Endarterectomy
por: Gerfer, Stephen, et al.
Publicado: (2023)

The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease
por: Wu, Zhonghua, et al.
Publicado: (2019)

CYP2C19 genotype and platelet aggregation test-guided dual antiplatelet therapy after off-pump coronary artery bypass grafting: A retrospective cohort study
por: Yao, Haoyi, et al.
Publicado: (2022)

Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome
por: Abergel, Eitan, et al.
Publicado: (2010)

Association of −344C/T polymorphism in the aldosterone synthase (CYP11B2) gene with cardiac and cerebrovascular events in Chinese patients with hypertension
por: Wang, Lili, et al.
Publicado: (2020)

Low TLR7 gene expression in atherosclerotic plaques is associated with major adverse cardio- and cerebrovascular events
por: Karadimou, Glykeria, et al.
Publicado: (2017)

Identification of potentially inappropriate medications with risk of major adverse cardio- and cerebrovascular events among elderly patients
por: Lima, Joana C. F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_chdvqk2hbp9v0niao2v035u928